Mapping the Nonstructural Transmembrane Proteins of Severe Acute Respiratory Syndrome Coronavirus 2.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 36 citations in OpenAlex.

1. Pathways in the brain, heart and lung influenced by SARS-CoV-2 NSP6 and SARS-CoV-2 regulated miRNAs: an in silico study hinting cancer incidence.Cardio-oncology (London, England) · 2025
   Article
2. The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery.The Journal of biological chemistry · 2025
   Article
3. Oligomeric assembly of the C-terminal and transmembrane region of SARS-CoV-2 nsp3.Journal of virology · 2024
   Article
4. Procoagulant Status and Fibrinolytic Activity in COVID-19 Patients during Illness and Convalescence.Biomedicines · 2023
   Article
5. Phylogenetic, Sequencing, and Mutation Analysis of SARS-CoV-2 Omicron (BA.1) and Its Subvariants (BA.1.1, BA.2) During the Fifth Wave of the COVID-19 Pandemic in the Iraqi Kurdistan Region.Cureus · 2023
   Article
6. Autophagy in Inflammatory Response against SARS-CoV-2.International journal of molecular sciences · 2023
   Review
7. A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19).Antibodies (Basel, Switzerland) · 2023
   Review
8. Molecular Epidemiology of the Norwegian SARS-CoV-2 Delta Lineage AY.63.Viruses · 2022
   Article
9. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19.Acta pharmacologica Sinica · 2022
   Review
10. Cytokines and microRNAs in SARS-CoV-2: What do we know?Molecular therapy. Nucleic acids · 2022
    Review
11. SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion.Viruses · 2022
    Review
12. Omicron BA.2 lineage spreads in clusters and is concentrated in Denmark.Journal of medical virology · 2022
    Article
13. Genome Profiling of SARS-CoV-2 in Indonesia, ASEAN and the Neighbouring East Asian Countries: Features, Challenges and Achievements.Viruses · 2022
    Article
14. Target genes used for biosensor development in COVID-19 diagnosis.Biosensors & bioelectronics · 2022
    Review
15. Structural biology of SARS-CoV-2: open the door for novel therapies.Signal transduction and targeted therapy · 2022
    Review
16. SARS-CoV-2 and the Nucleus.International journal of biological sciences · 2022
    Review
17. Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population.Vaccines · 2021
    Article
18. Identification of ZDHHC17 as a Potential Drug Target for Swine Acute Diarrhea Syndrome Coronavirus Infection.mBio · 2021
    Article
19. Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era.Indian journal of pharmacology
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as